David Amsellem analyst PIPER SANDLER

Currently, out of the existing stock ratings of David Amsellem - 248 which are a Buy (75.84%), 69 which are a Hold (21.1%), 10 which are a Sell (3.06%)

David Amsellem

Work Performance Price Targets & Ratings Chart

Analyst David Amsellem works at PIPER SANDLER and is covering the Healthcare sector with 641 price targets and ratings displayed on 33 stocks.

David Amsellem's average stock forecast success ratio is 51.08% with an average time for price targets to be met of 239.21 days.

Most recent stock forecast was given on RVNC, Revance Therapeutics at 20-Sep-2023.

Wall Street Analyst David Amsellem

Analyst best performing recommendations are on REPH (RECRO PHARMA).
The best stock recommendation documented was for NBIX (NEUROCRINE BIOSCIENCES) at 12/19/2013. The price target of $17 was fulfilled within 19 days with a profit of $7.88 (86.4%) receiving and performance score of 45.48.

Average potential price target upside

ADMS Adamas Pharmaceuticals AGN AKRX AMPH Amphastar Pharmaceuticals AMRX Amneal Pharmaceuticals ATRS Antares Pharma BDSI BioDelivery Sciences International BHC Bausch Health Companies COLL Collegium Pharmaceutical EGRX Eagle Pharmaceuticals ENDP Endo International plc HZNP Horizon Therapeutics PublicCompany INSY JAZZ Jazz Pharmaceuticals plc MNK NBIX Neurocrine Biosciences PCRX Pacira BioSciences RVNC Revance Therapeutics SUPN Supernus Pharmaceuticals TEVA Teva Pharmaceutical Industries CARA Cara Therapeutics EVFM Evofem Biosciences OGN OPTN OptiNose REPH Recro Pharma ASRT VTRS ALKS Alkermes plc AVDL Avadel Pharmaceuticals plc BXRX Baudax Bio HRMY Harmony Biosciences Holdings NOVN XERS Xeris Pharmaceuticals

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score



$0.28 (3.41%)


1 years 10 months 3 days ago

0/2 (0%)

$17.61 (51.68%)



$0.78 (9.49%)


1 years 11 months 2 days ago

0/4 (0%)

$2.47 (40.09%)



$-0.22 (-2.68%)


1 years 11 months 8 days ago

5/7 (71.43%)

$8.31 (32.04%)




1 years 11 months 8 days ago

2/5 (40%)

$11.51 (152.81%)




1 years 11 months 9 days ago

1/1 (100%)

$11.15 (36.14%)


Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is David Amsellem is most bullish on?

Potential upside of $30.85 has been obtained for RVNC (REVANCE THERAPEUTICS)

Which stock is David Amsellem is most reserved on?

Potential downside of $0.71 has been obtained for AMRX (AMNEAL PHARMACEUTICALS)

What Year was the first public recommendation made by David Amsellem?

On 2009

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart